Table 1.
Cases of EGPA complicated with MN.
| Author | Age/sex | Before treatment renal function (Cre mg/dL) | Other organ comorbidities | ANCA | NCGN/EOS | IF | Treatments | After treatments Cre (mg/dL)/proteinuria |
| (year) | Proteinuria | Other organ comorbidities | ||||||
|
| ||||||||
| Ayuzawa (2012) | 65/F | Decreased (Cre 0.9) | Purpura, neuropathy, pneumonia | Negative | +/+ | IgG1 > 4 | mPSL 1 g × 3 days PSL 40 mg (initial dose) |
Cre 0.6/CR |
| 9.9 g/gCre | Improved | |||||||
| Ram (2014) | 37/M | Decreased (Cre 2.3) | Respiratory syndromes, subcutaneous nodules, arthritis | Positive | +/ND | IgG | mPSL 15 mg/kg/day × 3 days PSL 0.5 mg/kg/day (initial dose) IVCY × 9 times, AZA 2 mg/kg/day |
Cre 1.2/CR |
| 8.7 g/day | ND | |||||||
| Mahmood (2019) | 63/F | Preserved (Cre ND) | Purpura, neuropathy, pneumonia | Positive | −/ND | IgG | Rituximab (regimen unknown) | ND/PR |
| 8.0 g/gCre | Improved | |||||||
| Kondo (2020) | 50/F | Preserved (Cre 0.54) | IgG4-related disease, neuropathy | Negative | −/− | IgG4 > 1 | PSL 0.8 mg/kg/day (initial dose) CsA 1.5 mg/kg/day (initial dose) MZB 3.0 mg/kg/day, IVIg × 3 times | ND/CR |
| 8.4 g/gCre | Neuropathy did not improve | |||||||
| Zhu (2019) | 50/M | Preserved (Cre 0.87) | Purpura, pneumonia | Positive | −/+ | IgG4, PLA2R | PSL 60 mg IVCY × 9 times | ND/CR |
| 6.4 g/gCre | ND | |||||||
| Our case | 70/F | Decreased (Cre 1.94) 0.63 g/gCre | Purpura, neuropathy, | Negative | −/− | IgG4 > 1 | mPSL 0.5 g × 3 days PSL 40 mg (initial dose) | Cre 0.86/CR |
| Improved | ||||||||
ANCA, anti-neutrophil cytoplasmic antigen; AZA, azathioprine; Cre, creatinine; CsA, cyclosporine; CR, complete remission; EOS, eosinophilic infiltration; IF, immunofluorescence staining; IVCY, intravenous cyclophosphamide; IVIg, intravenous immunoglobulin; mPSL, methylprednisolone; MZB, mizoribine; ND, no data; NCGN, necrotizing crescentic glomerulonephritis; PR, partial remission; PSL, prednisolone.